Zacks Investment Research
02 Nov 2026, 15:55 UTC · 59m ago
Impact · against what's priced in
Tarsus Pharmaceuticals (TARS) shows potential for upside based on analyst price targets and earnings revisions. However, as these are lagging indicators of market sentiment rather than new fundamental catalysts, the immediate impact is modest.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
Wall Street analysts have a mean short-term price target of $97.89 for Tarsus Pharmaceuticals, implying a 30.8% upside from $74.85.
Priced inanalysis of consensus targets
So whatThe most optimistic target of $116.00 suggests a 55% potential gain for the stock.
More positive than 76% of claims this week
Analysts agree that TARS will report better earnings than their previous estimates.
Continue reading
5 related stories
Wall Street analysts indicate a mean price target of $97.89, implying a 30.8% upside from the current price of $74.85, alongside positive earnings estimate revisions.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Priced indiscussion of general estimate revisions
So whatPositive revisions typically lead to an upward adjustment of EPS estimates ahead of the next earnings print.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Analysts indicate significant potential upside with a mean price target of $97.89 and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
59m ago
−2.1%
Price is moving against the score
$73.28 vs $74.85 close before publication (Oct 30) · not market-adjusted
TARS chart →
